Short Interest in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Declines By 40.7%

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 73,700 shares, a decrease of 40.7% from the April 15th total of 124,300 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is currently 0.1 days.

Shares of NASDAQ:BVXV traded up $0.11 during trading on Friday, reaching $1.31. 33,975 shares of the company’s stock traded hands, compared to its average volume of 103,767. The company has a debt-to-equity ratio of 2.71, a current ratio of 7.64 and a quick ratio of 7.64. BiondVax Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $4.19. The company has a 50-day simple moving average of $1.46 and a 200-day simple moving average of $1.65.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last released its earnings results on Monday, March 28th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.18). As a group, equities analysts expect that BiondVax Pharmaceuticals will post -0.41 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the business. Morgan Stanley lifted its position in BiondVax Pharmaceuticals by 24.3% in the second quarter. Morgan Stanley now owns 51,592 shares of the company’s stock valued at $148,000 after acquiring an additional 10,071 shares during the last quarter. Millennium Management LLC acquired a new position in BiondVax Pharmaceuticals during the second quarter worth about $33,000. Citadel Advisors LLC acquired a new stake in shares of BiondVax Pharmaceuticals in the third quarter valued at approximately $40,000. Finally, Envestnet Asset Management Inc. purchased a new position in shares of BiondVax Pharmaceuticals during the fourth quarter valued at approximately $118,000. Institutional investors and hedge funds own 2.96% of the company’s stock.

Several research analysts recently issued reports on the company. StockNews.com began coverage on BiondVax Pharmaceuticals in a research note on Friday. They issued a “sell” rating on the stock. Aegis assumed coverage on BiondVax Pharmaceuticals in a research note on Wednesday, January 26th. They issued a “buy” rating and a $7.00 target price for the company.

BiondVax Pharmaceuticals Company Profile (Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Featured Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.